BeiGene, Ltd. (HKG: 6160)

Market Cap	188.24B
Revenue (ttm)	26.04B
Net Income (ttm)	-6.64B
Shares Out	n/a
EPS (ttm)	-63.61
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	498,100
Average Volume	1,599,502
Open	133.40
Previous Close	133.90
Day's Range	133.40 - 138.70
52-Week Range	75.45 - 153.00
Beta	0.63
RSI	78.43
Earnings Date	Apr 29, 2025

About BeiGene

BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. Its commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 10,600
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6160

Financial Performance

In 2023, BeiGene's revenue was 2.46 billion, an increase of 73.65% compared to the previous year's 1.42 billion. Losses were -881.71 million, -56.00% less than in 2022.

Financial numbers in CNY